There is a lot of information to absorb in this NOM.
The Valutech report attached to the independent valuation makes extremely interesting (and promising) reading.
The following excerpts from this very extensive report caught my eye:-
"The commercialisation approach adopted by Alcidion, is a more subtle and organic approach than that adopted by the larger Information technology providers in the industry such as Allscripts Healthcare Solutions which undertakes very large and costly implementation of its integrated platform with the potentials for substantial disruption and cost overruns.
The Alcidion approach is one in which implementation of its platform is a much lower risk undertaking, but once the confidence of the hospital client is gained, the relationship is likely to be very long term and provide economic returns over a long period where the financial costs are not regarded as onerous because commercial advantages of implementation of the platform can be demonstrated. The company has also formed partnerships with other healthcare providers so that joint solutions can be used in a number of different hospitals and countries........
This approach can lead to an initial slow growth in revenues and short term losses associated with the need for more resources to integrate the platform with other clinical information systems in the hospital. However, once market traction is gained, revenues can grow substantially and because of the need to maintain integration with other systems operating in the hospital, support and maintenance income for the system can continue for a substantial period of more than ten years.
The development of the Alcidion intellectual property is substantially complete with little risk associated with commercialisation. Most further development will be refinement of existing technology and the addition of new features or integration with other clinical information systems found in hospitals. • Because of its success so far in providing solutions in the Australian hospital market, it is unlikely that Alcidion will experience unforeseen hurdles to its expansion of activities in the Australian market and it has experienced staff that will be able to assist in the company’s entry into the North American market"
DEFINITELY have a read of this report in full. What I have read validates my decision to invest in Alcidion.
